人人点人人爽爽人人片av亚洲,国产女人与公拘交在线播放,久久精品免费人成人a片 ,亚洲欧洲精品无码av

Quarkmed Dynamics

Quarkmed will keep moving forward, paying attention to hot topics in the industry, discussing the latest developments in the industry, and working with enterprises to promote new progress in medicine.

Partial Cooperative ClientsQuarkmed NewsTeam Style

Home>Quarkmed Dynamics

部分合作客戶

PARTIAL COOPERATIVE CLIENTS

加載更多+正在加載+

Quarkmed News

Share the latest trends and industry discussions of Quarkmed

MORE

Nectin-4 Radiopharmaceutical Development Hits the Accelerator!

2026-05-20

Target Introduction RNA and Protein Expression of Nectin-4 (proteinatlas.org) Overview: Nectin-4 (Neural cell adhesion molecule-related molecule 4), also known as Poliovirus Receptor-Related Protein 4 (PVRL4), is a type I transmembrane glycoprotein belonging to the Nectin subfamily of the immunoglob...

202026-05

In-Depth Analysis: The First B7-H3 Radiopharmaceutical Omburtamab's Failed Bid for FDA Approval

B7-H3: An IntroductionAs a hot target in tumor immunotherapy, B7-H3 has not only attracted fierce competition among multiple ADC (Antibody-Drug Conjugate) developers but has also garnered significant ...

202026-05

Quarkmed Invites You to SNMMI 2026: Exploring the Future of Nuclear Medicine

The 2026 SNMMI Annual Meeting will be held from May 30 to June 2, 2026, at the Los Angeles Convention Center. Quarkmed will be exhibiting at the event, and we warmly invite you to visit us at Booth 28...

192026-05

One Article to Understand the R&D Status of CXCR4-Targeted Nuclear Drugs!

CXCR4 Target and Related Nuclear Drugs IntroductionThe interactions between the CXCR4 receptor, its ligand CXCL12, and other interacting molecules, along with their roles in cell signaling. Image adap...

192026-05

How to Get Started with 225Ac Nuclear Drugs? This One is Enough!

Nuclear Drug: 225Ac-ch806Journal of Nuclear Medicine 2024; 00:1–7 This article analyzes the key data of preclinical studies on 225Ac nuclear drugs with examples. Published in December 2024 in th...

1 2 3 4

團(tuán)隊(duì)風(fēng)采

TEAM STYLE

Contact Us

010-86469979

Address：Ping An Fortune Center, Lize Financial Business District of Beijing

Follow the Wechat official account

? 夸克醫(yī)藥版權(quán)所有京ICP備2024074643號(hào)-1

Tel
010-86469979
Scan
Follow the Wechat official account
Inquiry
掃碼添加客服

人人点人人爽爽人人片av亚洲,国产女人与公拘交在线播放,久久精品免费人成人a片 ,亚洲欧洲精品无码av

About

Service

Advantage

Quarkmed Dynamics

Featured Services

Human Resources

Mail System

CTMS System

Quarkmed Dynamics

部分合作客戶

PARTIAL COOPERATIVE CLIENTS

Quarkmed News

Share the latest trends and industry discussions of Quarkmed

Nectin-4 Radiopharmaceutical Development Hits the Accelerator!

In-Depth Analysis: The First B7-H3 Radiopharmaceutical Omburtamab's Failed Bid for FDA Approval

Quarkmed Invites You to SNMMI 2026: Exploring the Future of Nuclear Medicine

One Article to Understand the R&D Status of CXCR4-Targeted Nuclear Drugs!

How to Get Started with 225Ac Nuclear Drugs? This One is Enough!

團(tuán)隊(duì)風(fēng)采

TEAM STYLE

Contact Us

010-86469979

Follow the Wechat official account

Follow the Wechat official account

掃碼添加客服